According to a report by Reports and Data, the global market for Immune BCG is expected to reach USD 73.02 million by 2028, with a compound annual growth rate (CAGR) of 4.5% during the forecast period. The report attributes the growth in the Immune BCG market to increasing demand for the vaccine to combat tuberculosis, rising emphasis on immunization in emerging economies, and technological advancements in vaccine and drug development processes.

Additionally, the Immune BCG is a crucial part of national childhood immunization programs in several countries and is also used to treat bladder cancer. These factors are expected to drive the demand for Immune BCG and fuel revenue growth in the market.

Get a sample PDF of the report, visit @

https://www.reportsanddata.com/download-free-sample/30

Immune BCG is made from a strain of attenuated live Mycobacterium bovis, found in cows, and is safe for humans. It is widely used to prevent tuberculosis and other infections caused by Mycobacterium species. The vaccine is also administered to protect against non-tuberculosis mycobacterial infections such as leprosy and to treat superficial carcinoma of the bladder. Tuberculosis is a significant cause of death worldwide, particularly in communities facing socioeconomic challenges.

Investment in research to understand mycobacterial immunology and develop strategies to prevent pulmonary tuberculosis in adolescents and adults has contributed to market growth. Clinical trials to evaluate the efficacy of the Immune BCG in preventing sustained Mycobacterium tuberculosis infections in high-risk populations are also expected to drive revenue growth in the market.

The Immune BCG is administered parenterally to infants worldwide, particularly in countries with high tuberculosis prevalence, as part of the Expanded Program on Immunization by the World Health Organization. In addition, the vaccine has several beneficial off-target effects on the immune system that offer protection against a broad spectrum of other infections, such as chest infections and diarrhea, among others. This is another key factor expected to drive the demand for Immune BCG and fuel market growth.

However, a global shortage of Immune BCG, manufacturing and supply chain issues, and the vaccine's ineffectiveness in controlling the tuberculosis epidemic are expected to limit market growth to some extent over the forecast period.

To know more about the latest insights of the report, visit @

https://www.reportsanddata.com/request-latest-insight/30

The report segments the Immune BCG market based on type, application, end use, and region. The immune Immune BCG segment is expected to account for the largest revenue share over the forecast period, attributed to increasing administration of the vaccine in neonates and young children to provide protection against childhood tuberculosis meningitis.

The pediatric segment is expected to register a robust revenue CAGR over the forecast period, owing to a sharp increase in birth rates across the globe, growing focus on development of robust TB control programs, rising demand for Immune BCG to prevent childhood tuberculosis, and emphasis on mandatory vaccination of neonates and young children. The hospital segment is expected to register significant revenue growth over the forecast period, attributed to increasing availability of vaccine in hospital settings, immunization of newborn babies, favorable reimbursement policies, availability of skilled professionals and advanced healthcare facilities, and implementation of TB control strategies in hospital settings.

North America is expected to register considerable revenue growth over the forecast period owing to rising focus on immunization of children and newborn babies in the United States, availability of cost-effective vaccine, and increasing initiatives to promote vaccination in the region.

Major companies included in the market report are Merck & Co., Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited (GSBPL), and Statens Serum Institut.

Request a customized copy of the report @

https://www.reportsanddata.com/request-customization-form/30

Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.  

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact:

John W, Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs

Browse for more reports…

https://www.reportsanddata.com/report-detail/advanced-ophthalmology-technologies-market

https://www.reportsanddata.com/report-detail/aortic-aneurysm-market